Evidence map›Paper›PMID 24958820›Full record

Trial reportJournal of clinical oncology : official journal of the American Society of Clinical Oncology2014

Human papillomavirus and overall survival after progression of oropharyngeal squamous cell carcinoma.

Carole Fakhry, Qiang Zhang, Phuc Felix Nguyen-Tan, David Rosenthal, Adel El-Naggar, Adam S Garden, Denis Soulieres, Andy Trotti, Vilija Avizonis, John Andrew Ridge and 3 more

Open access · bronzeAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 237 papers, 11 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
237citing papers in PubMed, 11 pooled it
42.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

237 citing papers in PubMed, 11 syntheses or guidelines pooled it, 542 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Trial
  13. Trial
  14. Trial
  15. Reduced-Dose Radiation Therapy for HPV-Associated Oropharyngeal Carcinoma (NRG Oncology HN002).Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2021
    Trial
  16. Impact of Neoadjuvant Durvalumab with or without Tremelimumab on CD8Clinical cancer research : an official journal of the American Association for Cancer Research · 2020
    Trial
  17. Trial
  18. Trial
  19. Article
  20. Article

177 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors at 1 institution in 1 country.

Carole FakhryCarole Fakhry, Johns Hopkins Medical Institutions; Milton J. Dance Jr Head and Neck Center, Baltimore, MD; Qiang Zhang, Jonathan Harris, Radiation Therapy Oncology Group Statistical Center; John Andrew Ridge, Fox Chase Cancer Center, Philadelphia, PA; David Rosenthal, Adel El-Naggar, Adam S. Garden, The University of Texas MD Anderson Cancer Center, Houston, TX; Andy Trotti, H. Lee Moffitt Cancer Center, Tampa, FL; Vilija Avizonis, Intermountain Medical Center, Murray, UT; Quynh-Thu Le, Stanford University Medical Center, Stanford, CA; Maura Gillison, Ohio State University Medical Center, Columbus, OH; Phuc Felix Nguyen-Tan, Denis Soulieres, Centre Hospitalier de l'Université de Montréal Hospital Notre Dame, Montreal, Canada. cfakhry@jhmi.edu.
Qiang ZhangCarole Fakhry, Johns Hopkins Medical Institutions; Milton J. Dance Jr Head and Neck Center, Baltimore, MD; Qiang Zhang, Jonathan Harris, Radiation Therapy Oncology Group Statistical Center; John Andrew Ridge, Fox Chase Cancer Center, Philadelphia, PA; David Rosenthal, Adel El-Naggar, Adam S. Garden, The University of Texas MD Anderson Cancer Center, Houston, TX; Andy Trotti, H. Lee Moffitt Cancer Center, Tampa, FL; Vilija Avizonis, Intermountain Medical Center, Murray, UT; Quynh-Thu Le, Stanford University Medical Center, Stanford, CA; Maura Gillison, Ohio State University Medical Center, Columbus, OH; Phuc Felix Nguyen-Tan, Denis Soulieres, Centre Hospitalier de l'Université de Montréal Hospital Notre Dame, Montreal, Canada.
Phuc Felix Nguyen-TanCarole Fakhry, Johns Hopkins Medical Institutions; Milton J. Dance Jr Head and Neck Center, Baltimore, MD; Qiang Zhang, Jonathan Harris, Radiation Therapy Oncology Group Statistical Center; John Andrew Ridge, Fox Chase Cancer Center, Philadelphia, PA; David Rosenthal, Adel El-Naggar, Adam S. Garden, The University of Texas MD Anderson Cancer Center, Houston, TX; Andy Trotti, H. Lee Moffitt Cancer Center, Tampa, FL; Vilija Avizonis, Intermountain Medical Center, Murray, UT; Quynh-Thu Le, Stanford University Medical Center, Stanford, CA; Maura Gillison, Ohio State University Medical Center, Columbus, OH; Phuc Felix Nguyen-Tan, Denis Soulieres, Centre Hospitalier de l'Université de Montréal Hospital Notre Dame, Montreal, Canada.
David RosenthalCarole Fakhry, Johns Hopkins Medical Institutions; Milton J. Dance Jr Head and Neck Center, Baltimore, MD; Qiang Zhang, Jonathan Harris, Radiation Therapy Oncology Group Statistical Center; John Andrew Ridge, Fox Chase Cancer Center, Philadelphia, PA; David Rosenthal, Adel El-Naggar, Adam S. Garden, The University of Texas MD Anderson Cancer Center, Houston, TX; Andy Trotti, H. Lee Moffitt Cancer Center, Tampa, FL; Vilija Avizonis, Intermountain Medical Center, Murray, UT; Quynh-Thu Le, Stanford University Medical Center, Stanford, CA; Maura Gillison, Ohio State University Medical Center, Columbus, OH; Phuc Felix Nguyen-Tan, Denis Soulieres, Centre Hospitalier de l'Université de Montréal Hospital Notre Dame, Montreal, Canada.
Adel El-NaggarCarole Fakhry, Johns Hopkins Medical Institutions; Milton J. Dance Jr Head and Neck Center, Baltimore, MD; Qiang Zhang, Jonathan Harris, Radiation Therapy Oncology Group Statistical Center; John Andrew Ridge, Fox Chase Cancer Center, Philadelphia, PA; David Rosenthal, Adel El-Naggar, Adam S. Garden, The University of Texas MD Anderson Cancer Center, Houston, TX; Andy Trotti, H. Lee Moffitt Cancer Center, Tampa, FL; Vilija Avizonis, Intermountain Medical Center, Murray, UT; Quynh-Thu Le, Stanford University Medical Center, Stanford, CA; Maura Gillison, Ohio State University Medical Center, Columbus, OH; Phuc Felix Nguyen-Tan, Denis Soulieres, Centre Hospitalier de l'Université de Montréal Hospital Notre Dame, Montreal, Canada.
Adam S GardenCarole Fakhry, Johns Hopkins Medical Institutions; Milton J. Dance Jr Head and Neck Center, Baltimore, MD; Qiang Zhang, Jonathan Harris, Radiation Therapy Oncology Group Statistical Center; John Andrew Ridge, Fox Chase Cancer Center, Philadelphia, PA; David Rosenthal, Adel El-Naggar, Adam S. Garden, The University of Texas MD Anderson Cancer Center, Houston, TX; Andy Trotti, H. Lee Moffitt Cancer Center, Tampa, FL; Vilija Avizonis, Intermountain Medical Center, Murray, UT; Quynh-Thu Le, Stanford University Medical Center, Stanford, CA; Maura Gillison, Ohio State University Medical Center, Columbus, OH; Phuc Felix Nguyen-Tan, Denis Soulieres, Centre Hospitalier de l'Université de Montréal Hospital Notre Dame, Montreal, Canada.
Denis SoulieresCarole Fakhry, Johns Hopkins Medical Institutions; Milton J. Dance Jr Head and Neck Center, Baltimore, MD; Qiang Zhang, Jonathan Harris, Radiation Therapy Oncology Group Statistical Center; John Andrew Ridge, Fox Chase Cancer Center, Philadelphia, PA; David Rosenthal, Adel El-Naggar, Adam S. Garden, The University of Texas MD Anderson Cancer Center, Houston, TX; Andy Trotti, H. Lee Moffitt Cancer Center, Tampa, FL; Vilija Avizonis, Intermountain Medical Center, Murray, UT; Quynh-Thu Le, Stanford University Medical Center, Stanford, CA; Maura Gillison, Ohio State University Medical Center, Columbus, OH; Phuc Felix Nguyen-Tan, Denis Soulieres, Centre Hospitalier de l'Université de Montréal Hospital Notre Dame, Montreal, Canada.
Andy TrottiCarole Fakhry, Johns Hopkins Medical Institutions; Milton J. Dance Jr Head and Neck Center, Baltimore, MD; Qiang Zhang, Jonathan Harris, Radiation Therapy Oncology Group Statistical Center; John Andrew Ridge, Fox Chase Cancer Center, Philadelphia, PA; David Rosenthal, Adel El-Naggar, Adam S. Garden, The University of Texas MD Anderson Cancer Center, Houston, TX; Andy Trotti, H. Lee Moffitt Cancer Center, Tampa, FL; Vilija Avizonis, Intermountain Medical Center, Murray, UT; Quynh-Thu Le, Stanford University Medical Center, Stanford, CA; Maura Gillison, Ohio State University Medical Center, Columbus, OH; Phuc Felix Nguyen-Tan, Denis Soulieres, Centre Hospitalier de l'Université de Montréal Hospital Notre Dame, Montreal, Canada.
Vilija AvizonisCarole Fakhry, Johns Hopkins Medical Institutions; Milton J. Dance Jr Head and Neck Center, Baltimore, MD; Qiang Zhang, Jonathan Harris, Radiation Therapy Oncology Group Statistical Center; John Andrew Ridge, Fox Chase Cancer Center, Philadelphia, PA; David Rosenthal, Adel El-Naggar, Adam S. Garden, The University of Texas MD Anderson Cancer Center, Houston, TX; Andy Trotti, H. Lee Moffitt Cancer Center, Tampa, FL; Vilija Avizonis, Intermountain Medical Center, Murray, UT; Quynh-Thu Le, Stanford University Medical Center, Stanford, CA; Maura Gillison, Ohio State University Medical Center, Columbus, OH; Phuc Felix Nguyen-Tan, Denis Soulieres, Centre Hospitalier de l'Université de Montréal Hospital Notre Dame, Montreal, Canada.
John Andrew RidgeCarole Fakhry, Johns Hopkins Medical Institutions; Milton J. Dance Jr Head and Neck Center, Baltimore, MD; Qiang Zhang, Jonathan Harris, Radiation Therapy Oncology Group Statistical Center; John Andrew Ridge, Fox Chase Cancer Center, Philadelphia, PA; David Rosenthal, Adel El-Naggar, Adam S. Garden, The University of Texas MD Anderson Cancer Center, Houston, TX; Andy Trotti, H. Lee Moffitt Cancer Center, Tampa, FL; Vilija Avizonis, Intermountain Medical Center, Murray, UT; Quynh-Thu Le, Stanford University Medical Center, Stanford, CA; Maura Gillison, Ohio State University Medical Center, Columbus, OH; Phuc Felix Nguyen-Tan, Denis Soulieres, Centre Hospitalier de l'Université de Montréal Hospital Notre Dame, Montreal, Canada.
Jonathan HarrisCarole Fakhry, Johns Hopkins Medical Institutions; Milton J. Dance Jr Head and Neck Center, Baltimore, MD; Qiang Zhang, Jonathan Harris, Radiation Therapy Oncology Group Statistical Center; John Andrew Ridge, Fox Chase Cancer Center, Philadelphia, PA; David Rosenthal, Adel El-Naggar, Adam S. Garden, The University of Texas MD Anderson Cancer Center, Houston, TX; Andy Trotti, H. Lee Moffitt Cancer Center, Tampa, FL; Vilija Avizonis, Intermountain Medical Center, Murray, UT; Quynh-Thu Le, Stanford University Medical Center, Stanford, CA; Maura Gillison, Ohio State University Medical Center, Columbus, OH; Phuc Felix Nguyen-Tan, Denis Soulieres, Centre Hospitalier de l'Université de Montréal Hospital Notre Dame, Montreal, Canada.
Quynh-Thu LeCarole Fakhry, Johns Hopkins Medical Institutions; Milton J. Dance Jr Head and Neck Center, Baltimore, MD; Qiang Zhang, Jonathan Harris, Radiation Therapy Oncology Group Statistical Center; John Andrew Ridge, Fox Chase Cancer Center, Philadelphia, PA; David Rosenthal, Adel El-Naggar, Adam S. Garden, The University of Texas MD Anderson Cancer Center, Houston, TX; Andy Trotti, H. Lee Moffitt Cancer Center, Tampa, FL; Vilija Avizonis, Intermountain Medical Center, Murray, UT; Quynh-Thu Le, Stanford University Medical Center, Stanford, CA; Maura Gillison, Ohio State University Medical Center, Columbus, OH; Phuc Felix Nguyen-Tan, Denis Soulieres, Centre Hospitalier de l'Université de Montréal Hospital Notre Dame, Montreal, Canada.
Maura GillisonCarole Fakhry, Johns Hopkins Medical Institutions; Milton J. Dance Jr Head and Neck Center, Baltimore, MD; Qiang Zhang, Jonathan Harris, Radiation Therapy Oncology Group Statistical Center; John Andrew Ridge, Fox Chase Cancer Center, Philadelphia, PA; David Rosenthal, Adel El-Naggar, Adam S. Garden, The University of Texas MD Anderson Cancer Center, Houston, TX; Andy Trotti, H. Lee Moffitt Cancer Center, Tampa, FL; Vilija Avizonis, Intermountain Medical Center, Murray, UT; Quynh-Thu Le, Stanford University Medical Center, Stanford, CA; Maura Gillison, Ohio State University Medical Center, Columbus, OH; Phuc Felix Nguyen-Tan, Denis Soulieres, Centre Hospitalier de l'Université de Montréal Hospital Notre Dame, Montreal, Canada.
Université de Montréal · CA

Funding

NRG Oncology Network Group Operations Center - GY9 BIQSFP Reports/BudgetsU10CA180868 · NCI · NRG ONCOLOGY FOUNDATION, INC. · PI NORMAN WOLMARK · 2014 to 2026
$206.8M
RTOG Foreign AccrualU10CA021661 · NCI · AMERICAN COLLEGE OF RADIOLOGY · PI CURRAN, WALTER J. · 1985 to 2013
$150.3M
Statistics CoreU10CA180822 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Mei-Yin C Polley · 2014 to 2026
$146.4M
RTOG Foreign AccrualsU10CA037422 · NCI · AMERICAN COLLEGE OF RADIOLOGY · PI BRUNER, DEBORAH WATKINS · 1985 to 2013
$30.4M
Gynecologic Oncology Group Specimen BankingU24CA114793 · NCI · GYNECOLOGIC ONCOLOGY GROUP · PI DISAIA, PHILIP J. · 2005 to 2014
$7.0M
NCI NIH HHS U10 CA021661NCI NIH HHS U10 CA037422NCI NIH HHS U10 CA180822NCI NIH HHS U10 CA180868NCI NIH HHS U10 CA21661NCI NIH HHS U10 CA37422NCI NIH HHS U24 CA114793
6 · The paper itself

Abstract

purposeRisk of cancer progression is reduced for patients with human papillomavirus (HPV) -positive oropharynx cancer (OPC) relative to HPV-negative OPC, but it is unknown whether risk of death after progression is similarly reduced. PATIENTS AND

methodsPatients with stage III-IV OPC enrolled onto Radiation Therapy Oncology Group trials 0129 or RTOG 0522 who had known tumor p16 status plus local, regional, and/or distant progression after receiving platinum-based chemoradiotherapy were eligible for a retrospective analysis of the association between tumor p16 status and overall survival (OS) after disease progression. Rates were estimated by Kaplan-Meier method and compared by log-rank; hazard ratios (HRs) were estimated by Cox models. Tests and models were stratified by treatment protocol.

resultsA total of 181 patients with p16-positive (n = 105) or p16-negative (n = 76) OPC were included in the analysis. Patterns of failure and median time to progression (8.2 v 7.3 months; P = .67) were similar for patients with p16-positive and p16-negative tumors. After a median follow-up period of 4.0 years after disease progression, patients with p16-positive OPC had significantly improved survival rates compared with p16-negative patients (2-year OS, 54.6% v 27.6%; median, 2.6 v 0.8 years; P < .001). p16-positive tumor status (HR, 0.48; 95% CI, 0.31 to 0.74) and receipt of salvage surgery (HR, 0.48; 95% CI; 0.27 to 0.84) reduced risk of death after disease progression whereas distant versus locoregional progression (HR, 1.99; 95% CI, 1.28 to 3.09) increased risk, after adjustment for tumor stage and cigarette pack-years at enrollment.

conclusionTumor HPV status is a strong and independent predictor of OS after disease progression and should be a stratification factor for clinical trials for patients with recurrent or metastatic OPC.

Indexed as

AdultAgedCarcinoma, Squamous CellCyclin-Dependent Kinase Inhibitor p16Disease ProgressionFemaleHumansMaleMiddle AgedNeoplasm ProteinsOropharyngeal NeoplasmsPapillomaviridaeProportional Hazards ModelsCDKN2A protein, humanCyclin-Dependent Kinase Inhibitor p16Neoplasm Proteins

Identifiers

PMID24958820
PMCPMC4195851
OpenAlexW2133539678

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.